Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 9Prostatic Neoplasms 4Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Stomach Neoplasms 1Skin Diseases 1Neoplasms, Unknown Primary 1Neoplasms by Site 1Multiple Myeloma 1Lymphoma 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Diseases 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Gemcitabine 4130-nm albumin-bound paclitaxel 4pembrolizumab 3napabucasin 3Paclitaxel 3Irinotecan 3selpercatinib 2pralsetinib 2patritumab 2Standard of Care 2Pemetrexed 2Nivolumab 2Fluorouracil 2Cyclophosphamide 2Cisplatin 2Carboplatin 2Ascorbic Acid 2Albumin-Bound Paclitaxel 2valrubicin 1sotorasib 1ribociclib 1relatlimab 1pamiparib 1osimertinib 1ipatasertib 1durvalumab 1dostarlimab 1cobimetinib 1atezolizumab 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms by Site × ipatasertib × Clear all
NCT04177108 2024-03-27

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Hoffmann-La Roche

Phase 3 Completed
242 enrolled 12 charts
Breast

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡